Reuters logo
BRIEF-Mitsubishi Tanabe Pharma updates license agreement with Kolon Life Secience on Invossa
December 20, 2017 / 7:44 AM / in a month

BRIEF-Mitsubishi Tanabe Pharma updates license agreement with Kolon Life Secience on Invossa

Dec 20 (Reuters) - Mitsubishi Tanabe Pharma Corp

* Says it notified Kolon Life Secience, Inc. (KLS) that the co seeks to cancel the license agreement between the co and KLS for Invossa, a cell therapy product for improvement of knee osteoarthritis symptoms

* Says it has started negotiation with KLS regarding the cancellation of the License Agreement

Source text in Japanese:goo.gl/3n39Ms

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below